BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nuki Y, Esaki M, Asano K, Maehata Y, Umeno J, Moriyama T, Nakamura S, Matsumoto T, Kitazono T. Comparison of the therapeutic efficacy and safety between tacrolimus and infliximab for moderate-to-severe ulcerative colitis: a single center experience. Scand J Gastroenterol. 2016;51:700-705. [PMID: 26818468 DOI: 10.3109/00365521.2016.1138239] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Jia X, Guo R, Hu Z, Liu J, Liu J, Li B, Yang Q, He J. Efficacy of infliximab, cyclosporine and tacrolimus on ulcerative colitis: A meta-analysis. Medicine (Baltimore) 2020;99:e22894. [PMID: 33126341 DOI: 10.1097/MD.0000000000022894] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Wu B, Tong J, Ran Z. Tacrolimus Therapy in Steroid-Refractory Ulcerative Colitis: A Review. Inflamm Bowel Dis. 2020;26:24-32. [PMID: 30980713 DOI: 10.1093/ibd/izz068] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
3 Kitayama M, Akazawa Y, Yoshikawa D, Higashi S, Morisaki T, Oda H, Ikeda M, Nakashima Y, Tabuchi M, Hashiguchi K, Matsushima K, Yamaguchi N, Kondo H, Nakao K, Takeshima F. Comparative efficacy of antitumor necrosis factor agents and tacrolimus in naïve steroid-refractory ulcerative colitis patients. Sci Rep 2020;10:12546. [PMID: 32719413 DOI: 10.1038/s41598-020-68828-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Wang JJ, Fan YH. Advances in research of tacrolimus for treatment of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2019; 27(13): 842-850 [DOI: 10.11569/wcjd.v27.i13.842] [Reference Citation Analysis]
5 Yamagami H, Nishida Y, Nagami Y, Hosomi S, Yukawa T, Otani K, Tanaka F, Taira K, Kamata N, Tanigawa T, Shiba M, Watanabe T, Fujiwara Y. A comparison of short-term therapeutic efficacy between infliximab and tacrolimus for moderate to severe ulcerative colitis. Rom J Intern Med 2017;55:151-7. [PMID: 28222041 DOI: 10.1515/rjim-2017-0012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
6 Liu YJ, Fan H, Zhen WW, Yu X, Chen JT, Wang CD. Pooled analysis of the comparative efficacy between tacrolimus and infliximab for ulcerative colitis. Medicine (Baltimore) 2018;97:e11440. [PMID: 30095612 DOI: 10.1097/MD.0000000000011440] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
7 Onodera M, Endo K, Kakuta Y, Kuroha M, Kimura T, Hiramoto K, Kanazawa Y, Negoro K, Shiga H, Kinouchi Y, Shimosegawa T. ATP-binding cassette subfamily B member 1 1236C/T polymorphism significantly affects the therapeutic outcome of tacrolimus in patients with refractory ulcerative colitis. J Gastroenterol Hepatol. 2017;32:1562-1569. [PMID: 28135009 DOI: 10.1111/jgh.13753] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
8 Saifuddin A, Harris A. Tacrolimus therapy in moderate to subacute ulcerative proctocolitis: a large single-centre cohort study. Frontline Gastroenterol. 2018;9:148-153. [PMID: 29588844 DOI: 10.1136/flgastro-2017-100888] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
9 Takeuchi K, Shimoyama T, Yamamoto T. Comparison of Safety and Efficacy of Tacrolimus versus Infliximab for Active Ulcerative Colitis. Dig Dis 2018;36:106-12. [PMID: 29050007 DOI: 10.1159/000481815] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
10 Iida T, Onodera K, Nakase H. Role of autophagy in the pathogenesis of inflammatory bowel disease. World J Gastroenterol 2017; 23(11): 1944-1953 [PMID: 28373760 DOI: 10.3748/wjg.v23.i11.1944] [Cited by in CrossRef: 85] [Cited by in F6Publishing: 87] [Article Influence: 17.0] [Reference Citation Analysis]
11 Lasa J, Olivera P. Efficacy of tacrolimus for induction of remission in patients with moderate-to-severe ulcerative colitis: A systematic review and meta-analysis. Arq Gastroenterol. 2017;54:167-172. [PMID: 28327826 DOI: 10.1590/s0004-2803.201700000-15] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
12 Hooper KM, Barlow PG, Stevens C, Henderson P. Inflammatory Bowel Disease Drugs: A Focus on Autophagy. J Crohns Colitis. 2017;11:118-127. [PMID: 27381462 DOI: 10.1093/ecco-jcc/jjw127] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 8.5] [Reference Citation Analysis]